Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
I-84: Adefovir Dipivoxil Therapy Significantly Decreases HIV RNA in Patients With High Level AZT-3TC Resistant HIV

September 25, 1998

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

GS-96-408 was a Gilead-funded study of what happened when adefovir (120 mg/day) was added to prior antiretroviral therapy in patients who still had detectable plasma HIV RNA. In this virologic substudy, plasma HIV RNA specimens from 142 patients were fully evaluated for viral load and genotypic mutations at baseline and 24 weeks. The participants in this study were heavily nucleoside experienced, most had previously taken at least 3 nucleosides (more than 50% AZT, more than 40% D4T), with at least 3 years' experience of AZT. Initially, they all had CD4 counts over 200 cells/mm3 and plasma viral loads over 2,500 copies/ml at baseline. 53% had viruses that had at least 3 AZT mutations consistent with high level resistance, and 76% had the 3TC mutation, M184V. Overall, participants that received adefovir had a plasma viral load decrease of .53 logs at 24 weeks. However, when the researchers looked at those participants who had baseline M184V mutations, the drop was .94 logs. This supports the in vitro finding that the 184 mutation increases susceptibility to adefovir. When participants had only pre-existing high level AZT resistance mutations, they did not have a meaningful drop in plasma HIV RNA, but when they had both AZT and 3TC resistance mutations at baseline, the addition of adefovir resulted in a .51 log drop. This data suggest that adefovir may be a very useful part of a new regimen in patients who have a rebound in plasma HIV RNA after having received regimens that contain 3TC in addition to AZT and other NRTIs; in NRTI-experienced patients who have not received prior 3TC, however, the addition of adefovir may not be useful.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Reference

Abstract: Adefovir dipivoxil therapy significantly decreases HIV RNA in patients with high level AZT-3TC resistant HIV
Authored by: Cherrington et al

See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More News and Research on Hepatitis B Prevention and Treatment



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement